...
首页> 外文期刊>The American Journal of Cardiology >Nonusefulness of Antithrombotic Therapy After Surgical Bioprosthetic Aortic Valve Replacement
【24h】

Nonusefulness of Antithrombotic Therapy After Surgical Bioprosthetic Aortic Valve Replacement

机译:手术生物疗法主动脉瓣膜置换后的抗血栓治疗的抗血栓治疗的不合适

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Controversy persists regarding the advisability of anticoagulation for the early period after biological surgical aortic valve replacement (AVR). We aim to examine the impact of various antithrombotic regimens on outcomes in a large cohort of biological AVR patients. Records of 1,111 consecutive adult patients who underwent surgical biological AVR at our institution between 2013 and 2017 were reviewed. Outcomes included stroke, bleeding, and death at 3 and 12 months. Treatment regimens included (1) no therapy, (2) anticoagulants (warfarin or Factor Xa inhibitors), (2) antiplateles (various), and (4) anticoagulants + antiplatelets. Kaplan-Meier analysis was used to track outcomes, and Cox-proportional hazards regression models were conducted to analyze effects of different therapies on adverse events.
机译:关于生物外科主动脉瓣置换术(AVR)后早期抗凝是否可取的争议依然存在。我们的目的是在一大组生物性AVR患者中研究各种抗血栓治疗方案对预后的影响。回顾了2013年至2017年间在我们机构接受外科生物AVR的1111名连续成年患者的记录。结果包括3个月和12个月时的中风、出血和死亡。治疗方案包括(1)不治疗,(2)抗凝剂(华法林或Xa因子抑制剂),(2)抗血小板(各种),以及(4)抗凝剂+抗血小板。Kaplan-Meier分析用于追踪结果,Cox比例风险回归模型用于分析不同疗法对不良事件的影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号